KNSA

Kiniksa Pharmaceuticals International, plc KNSA used its second-quarter 2026 earnings call to emphasize accelerating ARCALYST adoption and a higher full-year sales outlook. Management also moved KPL-387 into pivotal testing, adding a second major execution priority. The quarter’s financial results supplied context rather than the central message. Earnings of 30 cents per share matched the Zacks Consensus Estimate, while revenue of $243.6 million topped the $227.5 million consensus. Kiniksa Pharmaceuticals International, plc price-consensus-eps-surprise-chart | Kiniksa Pharmaceuticals International, plc Quote Chief executive officer Sanj Patel said ARCALYST momentum supported raising 2026 net product revenue guidance to $980 million-$995 million from $930 million-$945 million. Second-quarter ARCALYST revenue rose 55% year over year and increased by more than $29 million from the first quarter. Patel framed the gain as evidence of broader IL-1 pathway adoption in recurrent pericarditis. Chief financial officer Mark Ragosa said operating income reached $27.2 million and net income was $25.4 million. Cash, cash equivalents and short-term investments totaled $525.9 million, with no debt. Chief operating officer Ross Moat attributed growth to gains in both new and repeat prescribing. About 450 health care professionals wrote their first ARCALYST prescription during the quarter, lifting the launch-to-date prescriber base above 5,000. Roughly 150 additional prescribers moved into the repeat category from the first quarter. About 29% of the prescriber base has now written ARCALYST for two or more patients. Moat also highlighted investments in machine learning, predictive alerts and the Heart’s Home direct-to-consumer campaign. He said dissemination of updated clinical guidance is helping physicians use ARCALYST earlier in the treatment sequence. Chief medical officer John Paolini said Phase 2 data supported selecting a 300-milligram monthly subcutaneous dose for the PASTORALE Phase 3 study. Median time to treatment response and pain response was four days, while median time to C-reactive protein normalization was eight days. Paolini said efficacy remained durable across the monthly interval and tolerability was consistent with IL-1 pathway inhibition. PASTORALE is enrolling up to about 85 participants in an event-driven randomized-withdrawal study. The primary endpoint is time to first adjudicated pericarditis recurrence, and management continues to target a 2028-2029 commercial launch. A JPMorgan analyst asked whether the monthly KPL-387 profile could carry commercial significance. Chief operating officer Ross Moat cited prior market research showing about 75% of patients preferred the target profile over current commercial or investigational therapies. Moat added that about 92% of health care professionals indicated a high likelihood of prescribing the product to new patients. Management also said another IL-1 therapy could expand the overall treated population. A Wedbush analyst pressed for recurrence and follow-up details from the Phase 2 analysis. Chief Medical Officer John Paolini limited disclosure because the study remains ongoing, while emphasizing that 300-milligram monthly dosing maintained effect through the interval and biweekly dosing offered no incremental benefit. A Citi analyst asked whether first-recurrence patients contributed to ARCALYST demand. Chief Operating Officer Ross Moat said about 80% of new prescriptions came from patients with two or more recurrences, while about 20% came from the larger first-recurrence group. Management estimated that ARCALYST had reached about 21% of the 14,000-patient multiple-recurrence population. Chief executive officer Sanj Patel characterized that penetration level as evidence of remaining commercial runway. In response to Wells Fargo, Chief Financial Officer Mark Ragosa said year-to-date gross-to-net was 7.2%, down from 8.6% in the first quarter, mainly because of lower co-pay support. He expects the usual pattern of lower rates in the middle quarters and some increase in the fourth quarter. Management’s tone remained centered on disciplined commercial execution, continued patient penetration and timely delivery of KPL-387 milestones. The company also kept KPL-1161 on track for a Phase 1 study by year-end 2026, extending its IL-1 franchise toward a targeted quarterly dosing profile. KNSA carries a Zacks Rank #3 (Hold). Its Growth, Momentum and VGM Scores are all A, indicating strong characteristics in those styles, while the Value Score of D points to a weaker valuation profile.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The combination is less favorable than a Zacks Rank #1 or #2 (Buy) paired with A or B Style Scores, but the strong Growth, Momentum and VGM grades remain relevant for investors using those styles. The Zacks Rank can change as earnings estimates are revised after the reported results. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kiniksa Pharmaceuticals International, plc (KNSA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Kiniksa Pharmaceuticals International, plc (KNSA) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company. The upward trend in estimate revisions for this company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank. The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008. For Kiniksa Pharmaceuticals International, plc, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year. The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate: For the current quarter, the company is expected to earn $0.44 per share, which is a change of +91.3% from the year-ago reported number. Over the last 30 days, the Zacks Consensus Estimate for Kiniksa Pharmaceuticals International, plc has increased 26.09% because one estimate has moved higher compared to no negative revisions. For the full year, the company is expected to earn $1.39 per share, representing a year-over-year change of +85.3%. There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, one estimate has moved up for Kiniksa Pharmaceuticals International, plc versus no negative revisions. This has pushed the consensus estimate 10.9% higher. Thanks to promising estimate revisions, Kiniksa Pharmaceuticals International, plc currently carries a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500. Kiniksa Pharmaceuticals International, plc shares have added 28.7% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kiniksa Pharmaceuticals International, plc (KNSA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post earnings of $0.18 per share when it actually produced earnings of $0.27, delivering a surprise of +50%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Kiniksa Pharmaceuticals International, plc, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $243.6 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 7.09%. This compares to year-ago revenues of $156.8 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Kiniksa Pharmaceuticals International, plc shares have added about 54% since the beginning of the year versus the S&P 500's gain of 8.3%. While Kiniksa Pharmaceuticals International, plc has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Kiniksa Pharmaceuticals International, plc was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.35 on $240.72 million in revenues for the coming quarter and $1.25 on $938.98 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Twist Bioscience (TWST), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 3. This maker of synthetic DNA for the biotechnology industry is expected to post quarterly loss of $0.50 per share in its upcoming report, which represents a year-over-year change of -6.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Twist Bioscience's revenues are expected to be $114.5 million, up 19.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kiniksa Pharmaceuticals International, plc (KNSA) : Free Stock Analysis Report Twist Bioscience Corporation (TWST) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Alkermes plc ALKS reported break-even earnings for the second quarter of 2026 against the Zacks Consensus Estimate of a loss of 4 cents per share. The company had recorded earnings of 52 cents per share in the year-ago quarter. During the second quarter, the company recorded a change in the fair value of contingent consideration of $26.4 million related to the Avadel acquisition contingent value right (CVR) milestone. Alkermes reported total revenues of $496 million for the second quarter, up almost 27% from the year-ago quarter, driven by higher product sales. The top line beat the Zacks Consensus Estimate of $454 million. Shares of Alkermes were down in pre-market trading following the announcement of the earnings. The stock has rallied 88.5% so far this year compared with the industry’s rise of 2.6%. Image Source: Zacks Investment Research Alkermes derives revenues from the net sales of its proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia), Lybalvi (schizophrenia and bipolar I disorder) and the newly acquired sleep disorder drug, Lumryz. The metric also includes manufacturing and/or royalty revenues on net sales of products commercialized by partners. Sales of the proprietary products portfolio grew 34% year over year to $411.7 million during the second quarter, driven by solid demand across the commercial portfolio. Sales of proprietary products were above management’s guided range of $385-$405 million. Vivitrol sales increased 2.3% year over year to $124.5 million in the reported quarter. The metric beat the Zacks Consensus Estimate of $117 million. Aristada sales decreased 4.5% year over year to $96.7 million. The figure, however, beat the Zacks Consensus Estimate of $95 million. Lybalvi generated sales of $94 million, up 11.5% year over year in the reported quarter, due to increased total prescriptions. Its sales, however, missed the Zacks Consensus Estimate of $98 million. Lybalvi’s total prescriptions grew 18% year over year in the quarter. Newly acquired sleep disorder drug Lumryz recorded revenues worth $96.6 million in the second quarter. The metric beat the Zacks Consensus Estimate of $89 million. In February 2026, Alkermes completed the previously announced acquisition of Ireland-based Avadel Pharmaceuticals, which added the latter’s FDA-approved product, Lumryz, to its commercial portfolio. Lumryz is approved as the first and only once-at-bedtime oxybate for extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older with narcolepsy. Total manufacturing and royalty revenues increased 1.1% year over year to $84.3 million. Manufacturing and royalty revenues from Biogen’s multiple sclerosis drug, Vumerity, were $30.6 million. Royalty revenues from Xeplion and certain Invega products were $27.5 million in the second quarter. Research and development expenses totaled $112.9 million, up around 45.8% year over year. Selling, general and administrative expenses totaled $217.6 million, up around 27.4% year over year. As of June 30, 2026, Alkermes had cash and cash equivalents of $691.6 million compared with $538.2 million as of March 31, 2026. The company expects total revenues in the band of $1.73-$1.84 billion for 2026, unchanged from the previous expectation. Net sales of Vivitrol are expected to be in the range of $460-$480 million, while Aristada sales are anticipated in the range of $365-$385 million. Lybalvi’s net sales are expected in the $380-$400 million range. Net sales from Lumryz are expected to be in the range of $315-$335 million in 2026. Research and development expenses are anticipated in the range of $445-$485 million. Selling, general and administrative expenses are projected in the range of $890-$930 million. The company expects adjusted EBITDA to be in the range of $370-$410 million. Alkermes is developing alixorexton, a novel, investigational, oral, selective orexin 2 receptor agonist for the treatment of narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). In April 2026, the company initiated the phase III Brilliance studies, evaluating the safety and efficacy of alixorexton versus placebo in adults with NT1 and NT2. Alixorexton is also being evaluated in the phase II Vibrance-3 study for treating patients with IH. Top-line data from this study are expected by the end of 2026. In June 2026, the FDA granted an orphan drug designation (ODD) to alixorexton for the treatment of IH, and the European Commission granted ODD to alixorexton for the treatment of patients with narcolepsy. Alkermes plc price-consensus-eps-surprise-chart | Alkermes plc Quote Alkermes currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY, Kiniksa Pharmaceuticals KNSA and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.30, while estimates for 2027 have increased from $3.64 to $3.87 during the same time. HRMY shares have lost 3.8% year to date. Harmony Biosciences’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 25.16%. Over the past 60 days, estimates for Kiniksa Pharmaceuticals’ 2026 earnings per share have risen from $1.24 to $1.25, while estimates for 2027 have increased from $1.70 to $1.76 during the same time. KNSA shares have soared 54% year to date. Kiniksa Pharmaceuticals’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average surprise being 1.53%. Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 144.8% year to date. Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS) : Free Stock Analysis Report Liquidia Corporation (LQDA) : Free Stock Analysis Report Kiniksa Pharmaceuticals International, plc (KNSA) : Free Stock Analysis Report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in Kiniksa Pharmaceuticals International, plc? Here are five stocks we like better. ARCALYST revenue rose 55% year over year to $243.6 million in the second quarter, driven by growth in new and repeat prescribers. Kiniksa raised its 2026 revenue guidance to $980 million-$995 million from $930 million-$945 million. Kiniksa selected a 300-milligram monthly dose for KPL-387 after Phase II results showed rapid treatment and pain responses. The pivotal Phase III PASTEURAL trial is now enrolling and dosing patients, with a potential commercial launch projected for 2028-2029. The company reported $27.2 million in operating income and ended the quarter with $525.9 million in cash, generating approximately $58 million in net cash during the period. Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis treatment. The company raised its full-year 2026 ARCALYST revenue guidance to a range of $980 million to $995 million, from its prior range of $930 million to $945 million. Kiniksa also announced dose-focusing data for KPL-387 and said the pivotal Phase III PASTEURAL trial is enrolling and dosing patients. → Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit “Kiniksa is in a strong position more than halfway through 2026 as we continue to execute across our portfolio,” CEO and Chairman Sanj Patel said. Patel said the company anticipates a potential commercial launch of KPL-387 in the 2028 to 2029 timeframe. Chief Operating Officer Ross Moat said the second quarter represented the largest quarterly increase in ARCALYST net revenue since the product’s launch more than five years ago. He attributed the performance to the company’s commercial strategy, including investments in sales infrastructure, machine learning and artificial intelligence tools, direct-to-consumer outreach, and dissemination of clinical guidance. → This Tiny AI Supplier Could Be More Important Than the Chipmakers Kiniksa launched its targeted direct-to-consumer campaign, called Heart’s Home, in April. The campaign is designed to educate patients with recurrent pericarditis and encourage them to discuss ARCALYST with their healthcare providers. Moat said the campaign had reached thousands of patients and was showing early signs of engagement. The company has also focused on communicating the 2025 American College of Cardiology concise clinical guidance for recurrent pericarditis. Moat said the guidance recommends moving ARCALYST earlier in treatment following nonsteroidal anti-inflammatory drugs and colchicine, and before corticosteroids. Penetration in the multiple-recurrence patient population reached approximately 21% at the end of the second quarter, compared with about 18% at the end of 2025. About 450 additional healthcare professionals wrote their first ARCALYST prescription during the quarter, bringing the total prescriber base to more than 5,000 since launch. The number of healthcare professionals who had written prescriptions for two or more patients increased by about 150 from the first quarter. Approximately 29% of the prescriber base had written ARCALYST prescriptions for at least two patients. → 2 Stocks Built to Thrive If Inflation Refuses to Fade Moat said more than 25,000 healthcare professionals nationwide manage recurrent pericarditis patients. During the question-and-answer session, he said roughly 80% of new ARCALYST prescriptions were for patients with two or more recurrences, a population Kiniksa estimates at about 14,000 patients. The remaining approximately 20% were for patients experiencing their first recurrence, a group the company estimated at about 26,000 patients. Moat said Kiniksa has not observed a meaningful change in the patient profile receiving ARCALYST. Rather, he pointed to broader recognition and diagnosis of recurrent pericarditis as contributing to growth. Kiniksa said its Phase II/III program for KPL-387, an investigational IL-1 alpha and beta inhibitor, has moved into the Phase III portion following dose-focusing results. The company selected a 300-milligram subcutaneous monthly dose for the pivotal PASTEURAL study. Chief Medical Officer Dr. John Paolini said Phase II data showed the selected dose produced a median time to treatment response of four days, with a 95% confidence interval of three to six days. The median time to pain response was also four days, while the median time to C-reactive protein normalization was eight days, with a confidence interval of seven to nine days. Paolini said the 300-milligram monthly regimen demonstrated rapid and sustained activity throughout the monthly dosing interval and was generally well tolerated, consistent with the established safety profile of IL-1 pathway inhibition. The 300-milligram biweekly dose was efficacious but did not show incremental benefit over the monthly regimen, while the 100-milligram dose levels showed effects that did not support further development, according to the company. PASTEURAL is a placebo-controlled, event-driven randomized-withdrawal study designed to evaluate reduction in the risk of pericarditis recurrence. The trial will enroll up to approximately 85 patients who experience a recurrence despite conventional oral therapies. Patients who respond during a single-blind run-in period will be randomized either to continue KPL-387 at 300 milligrams monthly or switch to placebo. Paolini said the primary endpoint is time to first adjudicated pericarditis recurrence during the randomized-withdrawal period. Kiniksa said the trial design follows the approach used in its prior RHAPSODY Phase III program for ARCALYST. Chief Financial Officer Mark Ragosa said operating income for the second quarter was $27.2 million and net income was $25.4 million. ARCALYST collaboration profit increased 68% year over year to $176.1 million, growing faster than sales, according to the company. Operating expenses increased from a year earlier due to higher cost of goods sold tied to ARCALYST revenue, increased collaboration expenses, KPL-387 clinical trial and manufacturing costs, preclinical investments, and commercialization-related selling, general and administrative expenses. Kiniksa ended the quarter with $525.9 million in cash, representing approximately $58 million in net cash generation during the period. Ragosa said year-to-date gross-to-net was 7.2%, down from 8.6% in the first quarter. He attributed the change primarily to lower co-pay expense following modifications to the company’s support program at the beginning of the year. Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies. The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported strong second-quarter 2026 financial results, raised its full-year ARCALYST sales guidance, and advanced its cardiovascular pipeline with the Phase 3 launch of KPL-387 for recurrent pericarditis. Kiniksa increased its 2026 ARCALYST net sales guidance to $980 million-$995 million following strong prescription growth and higher patient adoption. Second-quarter revenue rose 55% year over year to $243.6 million, while net income increased to $25.4 million. Kiniksa (NASDAQ:KNSA) has initiated the pivotal Phase 3 PASTORALE trial for KPL-387 after positive Phase 2 results supported once-monthly dosing. The company ended the quarter with $525.9 million in cash, cash equivalents, and short-term investments and no debt. Management expects its current operating plan to remain cash flow positive on an annual basis. Kiniksa delivered second-quarter revenue of $243.6 million, up from $156.8 million in the prior-year period, driven by continued growth of ARCALYST for recurrent pericarditis. The company reported ARCALYST net product revenue of $243.6 million during the quarter and raised its full-year 2026 sales guidance to between $980 million and $995 million, up from its previous forecast of $930 million to $945 million. Management attributed the stronger outlook to continued growth in both new and repeat prescribers, resulting in a meaningful increase in patients receiving therapy. Kiniksa also announced positive progress for KPL-387. Interval data from the Phase 2 portion of its ongoing Phase 2/3 study showed rapid reductions in pain and inflammation with once-monthly subcutaneous dosing, supporting the launch of the pivotal Phase 3 PASTORALE trial, which is now enrolling and dosing patients. Financially, net income increased to $25.4 million from $17.8 million a year earlier despite higher investment in research, commercialization, and clinical development. The higher ARCALYST sales guidance reinforces the drug’s commercial momentum and suggests continued expansion within the recurrent pericarditis market. At the same time, advancing KPL-387 into Phase 3 provides Kiniksa with a potential next-generation therapy that management believes could offer convenient once-monthly dosing. If successful, the candidate could strengthen the company’s long-term growth strategy by expanding its cardiovascular inflammation franchise beyond ARCALYST. The company’s debt-free balance sheet and more than $525 million in cash also provide financial flexibility to continue investing in late-stage development programs, including KPL-387 and KPL-1161, while maintaining positive annual cash flow. Investors will likely monitor continued ARCALYST prescription growth, progress in the Phase 3 PASTORALE trial for KPL-387, and the planned initiation of the Phase 1 study for KPL-1161 by the end of 2026. Future updates on patient enrollment, clinical milestones, and commercial execution will be important indicators of the company’s long-term growth trajectory. Kiniksa Pharmaceuticals stock price

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Achieved the largest quarterly net revenue increase since launch, driven by the execution of a multi-pronged commercial strategy and shifting treatment paradigms in recurrent pericarditis. Expanded ARCALYST market penetration to approximately 21% of the multiple recurrence population, up from around 18% at the end of 2025, highlighting significant remaining growth runway. Attributed commercial success to disciplined sales infrastructure investments and the deployment of machine learning and AI to optimize the timing and messaging of field team interactions. Leveraged the 2025 ACC concise clinical guidance to move ARCALYST earlier in the treatment sequence, successfully shifting physician behavior away from corticosteroids toward IL-1 inhibition. Reported a record number of new patient enrollments and a broadening prescriber base, with approximately 450 new health care professionals writing their first ARCALYST prescription in Q2. Affirmed the 300mg monthly subcutaneous dose for KPL-387 based on Phase II data showing rapid onset of action and durable efficacy, supporting its advancement into the pivotal PASTORALE trial. Raised full-year 2026 revenue guidance to between $980 million and $995 million, reflecting sustained commercial momentum and increased patient demand. Targeting a potential commercial launch for KPL-387 in the 2028 to 2029 timeframe to extend leadership in the recurrent pericarditis market with a monthly dosing profile. Initiated the Phase III PASTORALE study, an event-driven randomized withdrawal trial designed to measure the reduction in risk of pericarditis recurrence as the primary demonstration of efficacy. Progressing KPL-1161, an Fc-modified IL-1 alpha and beta inhibitor, with plans to initiate a Phase I study by the end of 2026 to target quarterly dosing. Anticipate that the operating plan and current cash balance of $525.9 million provide sufficient runway to execute on both commercial growth and pipeline advancement. Operating expenses increased year-over-year due to higher cost of goods sold, collaboration profit-sharing, and intensified R&D spending for the KPL-387 pivotal program. Gross-to-net adjustments reached 7.2% year-to-date, primarily influenced by strategic changes to patient co-pay support programs implemented at the start of the year. Collaboration profit grew 68% year-over-year to $176.1 million, outpacing sales growth and demonstrating the operating leverage of the commercial model. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management attributed the growth to a culmination of flawless execution, including AI-driven predictive alerts for patient flares and the 'Heart's Home' DTC campaign. Confirmed that the 21% penetration rate in the multiple recurrence population represents a substantial opportunity for continued expansion into the broader 40,000-patient label. Noted no major changes in patient phenotype, but observed improved diagnosis rates as cardiologists better differentiate between index episodes and recurrent disease. Explained that gross-to-net is typically highest in Q1 and lower in Q2/Q3, with current favorability driven by optimized co-pay support structures. Stated that KPL-387's median time to treatment response of 4 days is consistent with the robust efficacy seen in the prior RHAPSODY trials for ARCALYST. Highlighted market research showing 75% of patients prefer the KPL-387 target profile (monthly dosing) over current commercial or other investigational therapies. The study is designed to provide supplemental label information to assist clinicians in transitioning patients from NSAIDs, corticosteroids, or other IL-1 inhibitors to KPL-387. Aims to establish clear dosing administration guidelines to facilitate transitioning patients who are experiencing disease recurrence despite conventional oral therapies.

– ARCALYST® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –– KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 –– KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 28, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported second quarter 2026 financial results and recent portfolio execution. “In the second quarter, Kiniksa continued to drive growth in new and repeat prescribers of ARCALYST in recurrent pericarditis, which led to a meaningful increase in patients on therapy. As a result, we have raised our 2026 ARCALYST net sales guidance to between $980 and $995 million,” said Sanj K. Patel, Chairman & Chief Executive Officer of Kiniksa. “In our clinical portfolio, KPL-387 Phase 2 data supported initiation of the pivotal Phase 3 trial, PASTORALE, which is now enrolling and dosing patients. We are excited to advance KPL-387 with its target product profile of once-monthly subcutaneous dosing in a liquid formulation. We expect to bring this potential additional treatment option to patients in the 2028/2029 timeframe. Additionally, we continue to develop KPL-1161 with a target profile of once-quarterly dosing and are on track to initiate a Phase 1 trial by the end of this year.” Portfolio ExecutionARCALYST (IL-1α and IL-1β cytokine trap) ARCALYST net product revenue was $243.6 million for the second quarter of 2026. As of the end of the second quarter of 2026, approximately 21% of the 14,000 multiple-recurrence patients were actively on ARCALYST treatment. Since launch, more than 5,000 prescribers have written ARCALYST prescriptions for recurrent pericarditis. As of the end of the second quarter of 2026, average total duration of ARCALYST therapy in recurrent pericarditis was approximately 3 years, in line with the median duration of disease. KPL-387 (monoclonal antibody IL-1 receptor antagonist) Kiniksa today announced data from an interval analysis of the ongoing KPL-387 Phase 2/3 trial in recurrent pericarditis. The Phase 2 dose-focusing portion of the trial is designed to evaluate the dose response and safety of different subcutaneously (SC) administered KPL-387 dose regimens and to support dose selection for the pivotal Phase 3 portion of the trial. Kiniksa is enrolling and dosing patients in PASTORALE, the pivotal Phase 3 portion of the Phase 2/3 clinical trial. Kiniksa is also conducting a supplemental Phase 2 Transition to KPL-387 Monotherapy Dosing & Administration Study evaluating the efficacy and safety of dosing regimens used to transition patients from standard therapies to KPL-387 monotherapy. ________________* Reported as median (95% confidence interval).1 Treatment Response is defined as Pain Response (NRS score ≤ 2 on the 11-point daily pericarditis pain NRS pain scale) and at least one CRP level ≤ 0.5 mg/dL within 7 days before or after the Pain Response.2 CRP Normalization is defined as CRP ≤ 0.5 mg/dL. KPL-1161 (Fc-modified monoclonal antibody IL-1 receptor antagonist) Kiniksa is conducting preclinical development activities with KPL-1161 with a target profile of quarterly SC dosing. The company expects to initiate a Phase 1 first-in-human clinical trial by the end of 2026. Financial Results Total revenue for the second quarter of 2026 was $243.6 million, compared to $156.8 million for the second quarter of 2025. Total operating expenses for the second quarter of 2026 were $216.4 million, compared to $136.6 million for the second quarter of 2025, and comprised the following: Net income for the second quarter of 2026 was $25.4 million, compared to $17.8 million for the second quarter of 2025. As of June 30, 2026, Kiniksa had $525.9 million of cash, cash equivalents, and short-term investments and no debt. Financial Guidance Kiniksa expects 2026 ARCALYST net product revenue of between $980 million and $995 million, compared to prior guidance of between $930 million and $945 million. Kiniksa expects its current operating plan to remain cash flow positive on an annual basis. Conference Call Information Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, July 28, 2026, to discuss second quarter 2026 financial results and recent portfolio execution. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. To access the webcast, please visit the Investors and Media section of Kiniksa’s website. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com. About ARCALYSTARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). The FDA granted Breakthrough Therapy designation to ARCALYST for the treatment of recurrent pericarditis in 2019 and Orphan Drug exclusivity to ARCALYST in 2021 for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021. IMPORTANT SAFETY INFORMATION ABOUT ARCALYST ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection). While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection. Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST. Medicines that affect the immune system may increase the risk of getting cancer. Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction. Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides. Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose. For more information about ARCALYST, talk to your doctor and see the Product Information. About KPL-387KPL-387 is an independently developed, investigational, fully human immunoglobulin G2 (IgG2) monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling of the cytokines IL-1α and IL-1β. Kiniksa believes KPL-387 could expand the treatment options for recurrent pericarditis patients by potentially enabling dosing with a single monthly SC self-injection in a liquid formulation. In October 2025, the FDA granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis. About PASTORALEPASTORALE is a double-blind, placebo controlled, randomized withdrawal (RW) study enrolling up to approximately 85 patients with recurrent pericarditis. In the first period, a single-blind run-in (RI), all participants will receive KPL-387 while conventional oral pericarditis medications are weaned and discontinued. Participants achieving Clinical Response in the RI period will then be randomized in a 1:1 ratio to receive either KPL-387 300 mg SC once-monthly or placebo in an event-driven, double-blind, RW period. The primary efficacy endpoint is time to first-adjudicated pericarditis recurrence during the RW period. Participants in the RW period may be eligible to enter a long-term extension. About KPL-1161KPL-1161 is an independently developed, investigational, Fc-modified IgG2 monoclonal antibody that binds IL-1R1, inhibiting the signaling of the cytokines IL-1α and IL-1β, with a target profile of quarterly SC dosing. Kiniksa is currently engaging in preclinical development activities for KPL-1161. Forward-Looking StatementsThis press release contains forward-looking statements. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our expectation that ARCALYST 2026 net product revenue will be between $980 million and $995 million; our expectation to begin commercialization of KPL-387 in 2028 or 2029; our belief that we are on track to initiate a Phase 1 first-in-human clinical trial of KPL-1161 by the end of 2026; our expectation that our current operating plan will remain cash flow positive on an annual basis; our target profile of quarterly subcutaneous dosing for KPL-1161; our beliefs about the mechanisms of our assets and potential impact of their approach; statements regarding our belief about the future of our commercial opportunities; and our belief that our portfolio of assets offers the potential for differentiation. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials, including the data from the interval analysis of our Phase 2 clinical trial of KPL-387 in recurrent pericarditis; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products and product candidates; raw material, important ancillary product and drug substance and/or drug product shortages; business development activities and their impact on our financial performance and strategy; changes in our operating plan, business development strategy or funding requirements; existing or new competition; current and future healthcare reforms, including those affecting the delivery of or payment for healthcare products and services; and the impact of global economic policy, including any uncertainty in national and international markets. These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. Every Second Counts! ® Kiniksa Investor & Media ContactJonathan Kirshenbaum(781) [email protected]

This article first appeared on GuruFocus. ARCALYST Revenue: $214.3 million in Q1 2026, a 56% year-over-year increase. Full-Year Revenue Guidance: Raised to $930 million to $945 million from previous $900 million to $920 million. Net Income: Increased to $22.6 million in Q1 2026 from $8.5 million in Q1 2025. ARCALYST Collaboration Profit: Grew 73% year-over-year to $151.2 million. Cash Balance: Ended Q1 2026 with $468.1 million, representing $54 million of net cash generation. New Prescribers: Approximately 400 new prescribers in Q1 2026, bringing the total to over 4,550. Repeat Prescribers: Approximately 1,320 prescribers have prescribed ARCALYST multiple times. Warning! GuruFocus has detected 9 Warning Sign with SEI. Is KNSA fairly valued? Test your thesis with our free DCF calculator. Release Date: April 28, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Kiniksa Pharmaceuticals International PLC (NASDAQ:KNSA) reported strong revenue growth for ARCALYST, with sales reaching $214.3 million in the first quarter of 2026, a 56% increase year-over-year. The company raised its full-year 2026 revenue guidance to $930 million to $945 million, up from the previous guidance of $900 million to $920 million. Kiniksa's financial position remains robust, with a cash balance of $468.1 million and positive cash flow, enabling continued investment in growth opportunities. The company is advancing its clinical pipeline, with the KPL-387 Phase 2, Phase 3 study in recurrent pericarditis on track, and plans to start a Phase 1 study for KPL-1161 by the end of the year. Kiniksa has launched a targeted direct-to-consumer campaign, 'Hearts Home,' to increase awareness and adoption of ARCALYST among recurrent pericarditis patients, leveraging digital innovation and AI for cost-effective outreach. Despite the strong performance, Kiniksa faces industry-wide headwinds related to co-pay resets and changes in insurance plans, which could impact future revenue growth. The company's gross to net increased in Q1 compared to the prior quarter, although it was lower than Q1 of 2025, indicating potential fluctuations in financial metrics. There is a significant awareness gap, with only 14% of recurrent pericarditis patients being unaided aware of ARCALYST, which could limit market penetration. The transition to KPL-387 monotherapy involves complex clinical trials and regulatory processes, which could pose challenges in terms of time and resource allocation. Kiniksa's growth strategy relies heavily on the success of its clinical trials and commercialization efforts, which are subject to regulatory approvals and market dynamics. Q: Can you discuss the early impact of the direct-to-consumer (DTC) campaign and future plans to accelerate demand? A: Ross Moat, Chief Operating Officer, explained that the DTC campaign is in its early stages and aims to educate recurrent pericarditis patients about ARCALYST. The campaign targets patients to encourage discussions with healthcare providers, as ARCALYST is prescribed in about 80% of cases when patients inquire. The company is also focusing on digital marketing and peer-to-peer education to increase awareness and adoption. Q: For KPL-387, what endpoints are most important for dose selection moving to Phase 3? A: John Paolini, Chief Medical Officer, highlighted that the Phase 2 trial will focus on the time of onset, magnitude of suppression of pain and inflammation, and durability of response. These elements will help define the PK/PD relationship and affirm the therapeutic concentration and dose level for Phase 3. Q: Is the increased marketing spend primarily due to the DTC campaign, or are there other factors? A: Mark Ragosa, Chief Financial Officer, noted that SG&A expenses increased due to personnel-related costs and sales and marketing initiatives. The DTC campaign is part of a broader digital marketing strategy, and while specific guidance on spending wasn't provided, SG&A has remained consistent as a percentage of sales. Q: How does the transition study for KPL-387 differ in treatment duration, and why was 16 weeks chosen? A: John Paolini explained that the 16-week duration is designed to transition patients from other therapies to KPL-387, achieving monotherapy within this period. The study allows for a long-term extension of up to two years, providing a comprehensive view of the transition process. Q: What impact have reimbursement and referral patterns had on new patient starts for ARCALYST? A: Ross Moat stated that reimbursement remains strong across payer mixes, and referral patterns are supported by centers of excellence and initiatives like the AHA's addressing recurrent pericarditis. The company focuses on educating physicians and patients to increase awareness and adoption. For the complete transcript of the earnings call, please refer to the full earnings call transcript.